Literature DB >> 30025200

Hepatitis B virus infection and risk of non-alcoholic fatty liver disease: A population-based cohort study.

Liguo Zhu1,2, Jie Jiang1, Xiangjun Zhai1, Aileen Baecker2, Hong Peng1, Jiao Qian1, MingHao Zhou1, Ci Song3, Yan Zhou4, Jianfang Xu5, Hongjian Liu6, Dong Hang3, Zhibin Hu3, Hongbin Shen3, Zuo-Feng Zhang2, Fengcai Zhu1.   

Abstract

BACKGROUND & AIMS: Although non-alcoholic fatty liver disease (NAFLD) has been studied extensively, the potential risk factors for NAFLD among chronic hepatitis B (CHB) patients have not been fully known.
METHODS: A population-based cohort of adult CHB patients without a history of alcohol drinking or NAFLD were recruited and followed up from October 2012 to January 2015 in Jiangsu province, China. Using Cox proportional hazards regression model, potential risk factors including viral and metabolic factors for NAFLD were evaluated.
RESULTS: Two thousand three hundred and ninety-three adult CHB patients (mean age 50.7 ± 13.2 years) were included in the cohort. With 4429 person-years of follow-up, 283 individuals progressed to NAFLD with an incidence rate of 63.89/1000 person-years. Overweight and obese CHB patients had an increased risk of NAFLD (overweight adjusted hazard ratio [HR], 3.10; 95% CI, 2.29-4.18; obese HR, 8.52; 95%CI, 5.93-12.25) compared to normal weight carriers. The incidence of NAFLD was associated with concurrent type 2 diabetes mellitus (DM) (HR, 1.88; 95%CI, 1.15-3.08). However, no associations between viral factors with NAFLD incidence rate were identified. In a subgroup of participants with concurrent type 2 DM, detectable HBV DNA levels were negatively associated with the development of NAFLD (HR, 0.37; 95%CI, 0.14-0.98). There was super-multiplicative interaction between BMI and gender with respect to incidence of NAFLD, with an ROR of 2.08 (95%CI, 1.02-4.23).
CONCLUSION: Metabolic factors play an important role in the presence of NAFLD among Chinese CHB patients. However, viral replication factors are not related to NAFLD except among those with concurrent type 2 DM.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990BMIzzm321990; zzm321990NAFLDzzm321990; HBsAg carriers; diabetes mellitus

Mesh:

Year:  2018        PMID: 30025200      PMCID: PMC6309470          DOI: 10.1111/liv.13933

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  29 in total

1.  Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.

Authors:  Zobair M Younossi; Munkhzul Otgonsuren; Linda Henry; Chapy Venkatesan; Alita Mishra; Madeline Erario; Sharon Hunt
Journal:  Hepatology       Date:  2015-10-24       Impact factor: 17.425

Review 2.  Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients.

Authors:  Mariana V Machado; António G Oliveira; Helena Cortez-Pinto
Journal:  J Gastroenterol Hepatol       Date:  2011-09       Impact factor: 4.029

3.  Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center.

Authors:  Ji Young Lee; Kang Mo Kim; Sung Gyu Lee; Eunsil Yu; Young-Suk Lim; Han Chu Lee; Young-Hwa Chung; Yung Sang Lee; Dong-Jin Suh
Journal:  J Hepatol       Date:  2007-03-06       Impact factor: 25.083

4.  Hepatitis B virus infection and fatty liver in the general population.

Authors:  Vincent Wai-Sun Wong; Grace Lai-Hung Wong; Winnie Chiu-Wing Chu; Angel Mei-Ling Chim; Arlinking Ong; David Ka-Wai Yeung; Karen Kar-Lum Yiu; Shirley Ho-Ting Chu; Hoi-Yun Chan; Jean Woo; Francis Ka-Leung Chan; Henry Lik-Yuen Chan
Journal:  J Hepatol       Date:  2011-10-23       Impact factor: 25.083

5.  [A cohort study of hepatitis B virus carriers progressing to chronic hepatitis in Jiangsu province, 2012-2014].

Authors:  L G Zhu; J Jiang; C Song; Y Zou; J F Xu; H J Liu; H Peng; Z B Hu; F C Zhu; H B Shen; X J Zhai
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2016-11-10

6.  Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma.

Authors:  Kook Hwan Kim; Hye-Jun Shin; Kyeongjin Kim; Hyun Mi Choi; Sang Hoon Rhee; Hyung-Bae Moon; Hyeong Hoe Kim; Ung Suk Yang; Dae-Yeul Yu; Jaehun Cheong
Journal:  Gastroenterology       Date:  2007-03-24       Impact factor: 22.682

7.  Hepatitis B Virus X Protein Induces Hepatic Steatosis by Enhancing the Expression of Liver Fatty Acid Binding Protein.

Authors:  Yun-Li Wu; Xian-E Peng; Yi-Bing Zhu; Xiao-Li Yan; Wan-Nan Chen; Xu Lin
Journal:  J Virol       Date:  2015-12-04       Impact factor: 5.103

8.  Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors.

Authors:  Man-Man Wang; Gong-Sui Wang; Feng Shen; Guang-Yu Chen; Qin Pan; Jian-Gao Fan
Journal:  Dig Dis Sci       Date:  2014-05-18       Impact factor: 3.199

9.  Inverse association between hepatitis B virus infection and fatty liver disease: a large-scale study in populations seeking for check-up.

Authors:  Yuan-Lung Cheng; Yuan-Jen Wang; Wei-Yu Kao; Ping-Hsien Chen; Teh-Ia Huo; Yi-Hsiang Huang; Keng-Hsin Lan; Chien-Wei Su; Wan-Leong Chan; Han-Chieh Lin; Fa-Yauh Lee; Jaw-Ching Wu
Journal:  PLoS One       Date:  2013-08-22       Impact factor: 3.240

10.  Evaluation of the impact of hepatitis B vaccination in adults in Jiangsu province, China.

Authors:  Liguo Zhu; Xiangjun Zhai; Yefei Zhu; Weiguo Xu; Changjun Bao; Hong Peng; Qian Bian; Haitao Yang; Hua Wang; Zhibin Hu; Hongbing Shen
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

View more
  11 in total

1.  Clinical features and prognosis of COVID-19 patients with metabolic syndrome: A multicenter, retrospective study.

Authors:  Jian Wang; Li Zhu; Longgen Liu; Xuebing Yan; Leyang Xue; Songping Huang; Biao Zhang; Tianmin Xu; Fang Ji; Chunyang Li; Fang Ming; Yun Zhao; Juan Cheng; Kang Chen; Xiang-An Zhao; Dawen Sang; Xinying Guan; Xiaobing Chen; Xiaomin Yan; Zhaoping Zhang; Jiacheng Liu; Rui Huang; Chuanwu Zhu; Chao Wu
Journal:  Med Clin (Engl Ed)       Date:  2022-06-09

2.  Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease.

Authors:  Shang-Chin Huang; Hau-Jyun Su; Jia-Horng Kao; Tai-Chung Tseng; Hung-Chih Yang; Tung-Hung Su; Pei-Jer Chen; Chun-Jen Liu
Journal:  Gut Liver       Date:  2021-05-15       Impact factor: 4.519

3.  Effect of Non-alcoholic Fatty Liver Disease on Transaminase Levels and Transient Elastography in Patients with Chronic Hepatitis B.

Authors:  Asim Sharif; Zaigham Abbas; Samiuddin Ahmed; Shoukat Ali Samjo; Khurram Baqai
Journal:  Cureus       Date:  2019-10-25

4.  Clinic-pathological features of metabolic associated fatty liver disease with hepatitis B virus infection.

Authors:  Ming-Fang Wang; Bo Wan; Yin-Lian Wu; Jiao-Feng Huang; Yue-Yong Zhu; You-Bing Li
Journal:  World J Gastroenterol       Date:  2021-01-28       Impact factor: 5.742

5.  Hepatoprotective mechanism of Silybum marianum on nonalcoholic fatty liver disease based on network pharmacology and experimental verification.

Authors:  Guoyan Jiang; Chunhong Sun; Xiaodong Wang; Jie Mei; Chen Li; Honghong Zhan; Yixuan Liao; Yongjun Zhu; Jingxin Mao
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

Review 6.  Non-Alcoholic Fatty Liver Disease in HIV/HBV Patients - a Metabolic Imbalance Aggravated by Antiretroviral Therapy and Perpetuated by the Hepatokine/Adipokine Axis Breakdown.

Authors:  Simona Alexandra Iacob; Diana Gabriela Iacob
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-09       Impact factor: 5.555

7.  Clinical features and prognosis of COVID-19 patients with metabolic syndrome: A multicenter, retrospective study.

Authors:  Jian Wang; Li Zhu; Longgen Liu; Xuebing Yan; Leyang Xue; Songping Huang; Biao Zhang; Tianmin Xu; Fang Ji; Chunyang Li; Fang Ming; Yun Zhao; Juan Cheng; Kang Chen; Xiang-An Zhao; Dawen Sang; Xinying Guan; Xiaobing Chen; Xiaomin Yan; Zhaoping Zhang; Jiacheng Liu; Rui Huang; Chuanwu Zhu; Chao Wu
Journal:  Med Clin (Barc)       Date:  2021-06-17       Impact factor: 3.200

8.  Assessment of fibrotic burden among chronic hepatitis B virus-infected patients with normal transaminase level.

Authors:  Mi Young Jeon; Beom Kyung Kim; Seung Up Kim
Journal:  Clin Mol Hepatol       Date:  2018-09-19

Review 9.  Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion.

Authors:  Yi-Wen Shi; Rui-Xu Yang; Jian-Gao Fan
Journal:  World J Gastroenterol       Date:  2021-07-14       Impact factor: 5.742

10.  Prevalence and Incidence of Non-alcohol Fatty Liver Disease in Chronic Hepatitis B Population in Southeast China: A Community-Based Study.

Authors:  Yang Zheng; Kaijin Xu; Haiyang Hu; Mohamed S Draz; Wei Wu; Lanjuan Li
Journal:  Front Med (Lausanne)       Date:  2021-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.